NCT04282187 2026-03-16
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Phase 2 Recruiting
Clinical Trials
14 trialsNCT05177211 2025-12-15
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT05127174 2025-12-04
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT04817007 2025-09-10
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT03952039 2025-08-28
FREEDOM2
Celgene
Phase 3 Completed
NCT01420770 2025-03-05
Phase 2 Study of SAR302503 in Patients With Myelofibrosis
Bristol-Myers Squibb
Phase 2 Completed
NCT01420783 2025-03-05
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
Bristol-Myers Squibb
Phase 2 Completed
NCT01437787 2025-03-05
JAKARTA
Bristol-Myers Squibb
Phase 3 Completed
NCT01523171 2025-03-05
JAKARTA2
Bristol-Myers Squibb
Phase 2 Completed
NCT01585623 2025-03-05
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
Bristol-Myers Squibb
Phase 1 Completed
NCT01836705 2025-03-05
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03755518 2024-12-12
FREEDOM
Celgene
Phase 3 Terminated
NCT04955938 2024-07-31
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
University of Chicago
Phase 1 Withdrawn
NCT05524857 2024-04-23
Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
Columbia University
Phase 1 Terminated